Pharmacology Watch
RSSArticles
-
FDA Actions
In this section: The agency approves exciting new treatment for multiple sclerosis, green lights an injection for atopic dermatitis, gives the go ahead to an add-on treatment for Parkinson's disease, and signs off on a drug for Duchenne muscular dystrophy.
-
Vitamin D and Cancer Rates in Postmenopausal Women
Investigators determined vitamin D plus calcium did not reduce cancer rates significantly, but more research is needed.
-
Sciatica Drug Demonstrates Little Efficacy
The authors of a recent study concluded that treatment with pregabalin did not reduce the intensity of leg pain associated with sciatica significantly nor did it improve other outcomes significantly.
-
Study Shows Risks of Discontinuing Therapy in Venous Thromboembolism Patients
Patients with venous thromboembolism, which includes deep vein thrombosis and pulmonary embolism, are at risk for recurrence after discontinuing therapy, even if the event was unprovoked.
-
FDA Action
The FDA has approved brodalumab to treat adults with moderate-to-severe plaque psoriasis.
-
A Possible New Hope for Leukemia Patients
Treatment with blinatumomab resulted in significantly longer overall survival than chemotherapy among adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
-
Comparing Treatments for Atopic Dermatitis
A new interleukin-31 inhibitor is under evaluation for the treatment of atopic dermatitis.
-
Breakthrough in Rheumatoid Arthritis Treatment?
In a recent trial, baricitinib was associated with significant clinical improvements as compared with placebo and adalimumab.
-
Popular Drug Could Help Prevent Type 2 Diabetes
Does liraglutide play a role in the prevention of type 2 diabetes?
-
Antithrombotic Drug Use Associated with Higher Risk of Subdural Hematoma
This study suggests that the newer direct oral anticoagulants may be safer in this regard than warfarin therapy.